Balaxi Pharmaceuticals Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Balaxi Pharmaceuticals Limited generated cash of $48,661,000, which is less than the previous year. Cash used in financing activities reached the amount of $302,539,000 last year. Net change in cash is therefore $340,738,000.
Cash Flow
| 2016 | -1.15M | -21.78K | -1.09M |
|---|---|---|---|
| 2018 | -6.78M | -106.3K | 0 |
| 2020 | -140.61M | -1.82M | 180.96M |
| 2021 | 32K | -59.72M | 36.46M |
| 2023 | 60.75M | -105.65M | 255.12M |
| 2024 | 48.66M | -10.46M | 302.53M |
BALAXI.NS Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 282.16M | 71.89M | 39.8M | 1.02M | 23.04M | 219.64K |
Operating activities | ||||||
Net income | 20.15M | 569.22M | 443.29M | 88.73M | -7.69M | -1.16M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 20.98M | 17.52M | 2.97M | 75K | 19.9K | 21.83K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -64.88M | -249.73M | -461.67M | -242.40M | 0 | 18.20K |
Inventories | 228.55M | -63.19M | -127.85M | -8.32M | 0 | 0 |
Accounts payable | -54.80M | -145.95M | 191.46M | 27.66M | 898.8K | 0 |
Cash generated by operating activities | 48.66M | 60.75M | 32K | -140.61M | -6.78M | -1.15M |
Investing activities | ||||||
Purchases Of Investments | 0 | 19.21M | -34.16M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -6.92M | -149.79M | -25.56M | -1.82M | -106.3K | -38K |
Acquisitions Net | 0 | -19.21M | -33.65M | 0 | 0 | 0 |
Cash generated by investing activities | -10.46M | -105.65M | -59.72M | -1.82M | -106.3K | -21.78K |
Financing activities | ||||||
Common Stock Issued | 257.90M | 184.71M | 180.96M | 180.96M | 0 | 0 |
Payments for dividends | 0 | -4.98M | 0 | 0 | 0 | -1.09M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 60.40M | 79.82M | -211K | 0 | 0 | 0 |
Cash used in financing activities | 302.53M | 255.12M | 36.46M | 180.96M | 0 | -1.09M |
Net Change In Cash | 340.73M | 210.22M | -23.23M | 38.77M | -6.88M | -1.17M |
Cash at end of period | 622.90M | 282.12M | 16.56M | 39.8M | 16.15M | -959.66K |
| Data source | Data source | Data source | Data source | Data source | Data source |